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This guideline was developed to identify evidence-based best practices in haemophilia care delivery, and discuss
the range of care providers and services that are most important to optimize outcomes for persons with
haemophilia (PWH) across the United States. The guideline was developed following specific methods described
in detail in this supplement and based on the GRADE (Grading of Recommendations, Assessment,
Development and Evaluation approach). Direct evidence from published literature and the haemophilia
community, as well as indirect evidence from other chronic diseases, were reviewed, synthesized and applied to
create evidence-based recommendations. The Guideline panel suggests that the integrated care model be used
over non-integrated care models for PWH (conditional recommendation, moderate certainty in the evidence).
For PWH with inhibitors and those at high risk for inhibitor development, the same recommendation was
graded as strong, with moderate certainty in the evidence. The panel suggests that a haematologist, a
specialized haemophilia nurse, a physical therapist, a social worker and round-the-clock access to a specialized
coagulation laboratory be part of the integrated care team, over an integrated care team that does not include
all of these components (conditional recommendation, very low certainty in the evidence). Based on available
evidence, the integrated model of care in its current structure, is suggested for optimal care of PWH. There is a
need for further appropriately designed studies that address unanswered questions about specific outcomes and
the optimal structure of the integrated care delivery model in haemophilia.
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Introduction
The National Hemophilia Foundation (NHF) is dedi-
cated to finding better treatments and cures for all
bleeding disorders and to preventing the complications
of these disorders through education, advocacy and
research support. Through the efforts and guidance of
the NHF’s Medical and Scientific Advisory Council
(MASAC), an internationally renowned group of
expert scientists, physicians and other discipline spe-
cialists, NHF has long been engaged in advancing the
standard of clinical care and issuing treatment recom-
mendations for all bleeding disorders. In 2012, the
NHF held a strategic summit to develop a plan for
haemophilia care aligned with the priority settings of
the evolving US health care environment, which
included an increased emphasis on evidence-based
care. The summit report included a call for the NHF
to sponsor the production and maintenance of evi-
dence-based clinical practice guidelines (CPGs) [1].
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The goal of these CPGs is to support patient-centred
clinical decision-making and optimize haemophilia
care for each patient.
For its first guideline, NHF has chosen the topic of
Care Models for Haemophilia Management, and has
partnered with McMaster University to provide exper-
tise and support (Core Methods Group: MP, NS,
CHTY, AI, and HJS) in CPG development. A number
of guidance documents, including the 2013 World
Federation of Haemophilia Guidelines for the Man-
agement of Haemophilia, the 2008 European Princi-
ples of Haemophilia Care, and a 1995 statement from
the Association of Haemophilia Clinic Directors of
Canada, have advocated for comprehensive care as
the optimal model of care in individuals with haemo-
philia [2–4]. However, the effects of integrated care
on patient-important outcomes in this complex disease
have not been systematically synthesized and com-
pared to alternative models, and questions about the
ideal composition of services and providers for opti-
mal haemophilia care remain unanswered.
Care models for haemophilia management in
the United States
There are a variety of models used to deliver care to
persons with haemophilia (PWH) in the US, three of
which appear to operate currently [5]:
1. The integrated care model, also known as the
‘Comprehensive Care’ model or the ‘Hemophilia
Treatment Center (HTC)’ model. This term refers
to the continuous supervision of all medical and
psychosocial aspects affecting the haemophilia
patient and family, including supervision of home-
based treatment (either prophylaxis or on-demand)
[5–7]. It generally demands that all modalities of
care – access to care providers, as well as diagnos-
tic and therapeutic facilities – are available and
delivered in a single specialized centre, by a team
of health care providers. The composition of the
integrated care team varies, but generally adheres
to key components recommended by the World
Federation of Haemophilia, including a medical
director, a nurse coordinator, a physical therapist,
a psychosocial expert (e.g. social worker) and a
specialized coagulation laboratory [2]. Some inte-
grated care centres also participate in outreach
clinics or telehealth programmes. HTCs in the US
that deliver integrated care are organized into
regional and national networks that set standards
of care, organize professional education and train-
ing, and engage in data collection and analysis [8].
2. The specialist based care model, where a haema-
tologist (who may or may not have specific train-
ing in the management of haemophilia) provides
care in a non-specialized centre, such as a hospital
or medical office.
3. Care delivered by a non-specialist in a non-specia-
list setting. This may take the form of a family
physician delivering care in private practice, or an
emergency room (ER) physician delivering care in
an ER setting.
Often operating in conjunction with one of the
models listed above, and thus constituting a compo-
nent of the care model rather than an alternative
model, is pharmacy-based care. Private specialty
pharmacies (typically, national or regional for-profit
corporations) or HTC-affiliated pharmacies provide
factor concentrates and ancillary services related to
the provision of treatments directly to patients in
their homes, as per a physician’s medical prescrip-
tion.
We believe that the ‘No Care’ model, theoretically
indicating complete absence of care, does not cur-
rently operate in the US. Yet, this is likely the de facto
model of care for many individuals with haemophilia
who do not have access to care due to profound
resource constraints, particularly in developing coun-
tries or underserved minorities [9,10].
Different models of care delivery have different
implications for reimbursement and funding [11,12].
They may be more or less feasible to implement in a
given setting, depending on local health care
resources, culture, and patient values and preferences.
These different models may have a differential impact
on health outcomes in haemophilia [13–15].
Purpose of this guideline
The purpose of this guideline is to identify best prac-
tices in haemophilia care delivery, and discuss the
range of care providers and services that are most
important for PWH across the US.
This guideline was developed foremost for persons
living with haemophilia, and for providers of haemo-
philia care. In addition, the guideline is meant to be a
resource for hospitals and health care systems, Federal
and State programmes and policy makers, private and
public insurers, and other professionals in the health
sector who are responsible for developing and imple-
menting strategies to care for individuals with haemo-
philia and other bleeding disorders at the national,
regional and state levels.
Methods
The methods used to develop these guidelines adhered
to suggested principles for developing transparent,
evidence-based guidelines promoted by the Institute
of Medicine, the National Guideline Clearinghouse
and the GRADE (Grading of Recommendations,
Assessment, Development and Evaluation) Working
Group [16–20]. A brief summary of the methods
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followed and further details are provided in a com-
panion methods paper [21].
Guideline panel composition
The Guideline panel was composed of US and non-US
health care providers (including physicians, nurses,
physical therapists, and a genetic counsellor) with
expertise in haemophilia care, individuals with experi-
ence in health policy, health care financing, and
research related to haemophilia, PWH, parents of
PWH, persons with other rare diseases, and methodol-
ogists. (See section on Guideline panel.)
Guideline timeline and process
Two Guideline panel meetings were held, with support
from and direct involvement of the Core Methods
Group: June 2014 in Milwaukee, WI and May 2015 in
Chicago, IL. The goals of the first face-to-face panel
meeting were to educate panel members on the guide-
line development methods, and finalize and manage
declarations of conflicts of interest (COI). A draft set of
questions and outcomes was also generated, started by
discussing the results of large surveys of patient and
provider groups previously administered by the Core
Methods Group to identify potentially relevant ques-
tions and outcomes. Between the two meetings, the
Guideline panel was engaged to perform a number of
tasks, including: prioritizing the questions and out-
comes of relevance; reviewing the evidence profiles
(EP) and draft evidence to decision (EtD) tables gener-
ated by the Core Methods Group; providing structured
experiential data for areas of scarce evidence; and judg-
ing the indirectness of evidence from diseases other
than haemophilia. The goals of the second face-to-face
panel meeting were to review, appraise, modify as
needed and approve the versions of the EP prepared by
the Core Methods Group by summarizing the body of
evidence, panelist comments and providing explicit
consideration of the quality of evidence; and to review,
integrated and approve the EtD (inclusive of benefits
and harms, patients’ values and preferences, acceptabil-
ity, feasibility, equity and resource use) prepared by the
Core Methods Group, and finally, formulating the
guideline’s recommendations.
The panel graded recommendations as ‘strong’ or
‘weak’ for or against a specific intervention, as recom-
mended by the GRADE working group [22,23]. The
implications of strong recommendation for policy
makers is that it can be adapted as a policy in most
situations. For clinicians, most patients should receive
the recommended course of action. For patients, a
strong recommendation indicates a course of action
that most patients would adopt and only a small pro-
portion would not. On the other hand, a weak (also
called conditional) recommendation indicates that
policy making will require a more substantial debate
and involvement of many stakeholders. For clinicians,
different choices will be appropriate for different
patients. For patients, weak recommendations suggest
a course of action that many patients, but not all,
would adopt. Agreement on the wording of the rec-
ommendations was also reached during the panel
meeting by consensus of voting members.
After final review of the unabridged Guideline
report by the panel members and consultants, the
guidelines were presented to the Medical and Scientific
Advisory Council (MASAC) at the NHF’s Annual
Meeting in August 2015, Dallas, TX. All stakeholders
(including members of the public) were invited to this
meeting, after which the Guideline Report was posted
on a dedicated webpage, and public comments were
invited during a subsequent 6-week period.
Guideline questions and outcomes
The following clinical questions were selected by the
panel, and are addressed in this guideline:
1. Should integrated care vs. non-integrated care be
used for people with haemophilia?
2. For individuals with haemophilia, should a haema-
tologist, a specialized haemophilia nurse, a physi-
cal therapist, a social worker or round-the-clock
access to a specialized coagulation laboratory be
part of the integrated care team, vs. an integrated
care team with a lesser complement?
The panel agreed on a number of subgroups of
PWH to be specifically addressed in the guideline: dis-
ease severity (mild, moderate and severe haemophilia);
inhibitor status; age (paediatric, defined as age
17 years or younger, and the older population, defined
as age 65 years or older); and comorbidities (i.e. hep-
atitis C, HIV). The panel also agreed that when evi-
dence could not be found for people with
haemophilia, evidence from other chronic diseases,
such as congestive heart failure (CHF), chronic
obstructive pulmonary disease (COPD) and asthma
would be sought. These diseases were felt to share
some features with haemophilia, including chronicity,
high resource use, involvement over the life span (for
asthma) and large use of delivery of care via multidis-
ciplinary integrated models, on which a well-devel-
oped body of literature exists.
The outcomes identified as important to the deci-
sion-making process included mortality (or survival);
missed days of school or work; number of ER visits;
length of in-patient stay; quality of life; joint damage
or disease; educational attainment; patient adherence;
and patient knowledge. Many other outcomes, includ-
ing bleeding and bleeding rate, were considered but
not judged important enough to enter the final list of
outcomes.
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Results
Question 1: Should integrated care vs. non-
integrated care be used for people with
haemophilia?
The literature search for reports assessing models of
care in haemophilia or other chronic diseases for the
outcomes of interest retrieved the following: no ran-
domized controlled trials comparing integrated care to
non-integrated care for people with haemophilia; six
systematic reviews of 52 randomized controlled trials
comparing integrated care to non-integrated care for
people with asthma or chronic obstructive pulmonary
disease (four reviews), heart failure (one review) or
multiple chronic conditions (one review); eight non-
randomized studies that compared integrated care to
non-integrated care for people with haemophilia; and
43 non-randomized studies that provided data from
one group of people with haemophilia who received
integrated care. Of the 43 non-randomized studies in
haemophilia, 24 provided only descriptive (i.e. non-
quantitative) information, and were thus excluded. The
body of evidence provided by the retrieved studies was
summarized in an EP (see Fig. 1, Appendix S1–S2).
The overall quality of evidence was judged as moder-
ate. While there was very low quality evidence for two
outcomes (knowledge and days of school or work lost),
the direction of the effects was concordant (i.e. in
favour of integrated care vs. other models of care) for
all critical outcomes, several of which had moderate
quality evidence. Therefore, the overall quality was not
lowered. Although there was some debate about the
magnitude of the benefits, the panel felt that there was a
clear balance in favour of the integrated care option,
given the complete absence of health harms.
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Fig. 1. PRISMA flow diagram for care models in
the management of haemophilia.
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The panel felt that considerations on equity, feasi-
bility and acceptability favoured integrated care if
access to care and capacity were optimized, and
implementation focused on making integrated care
available to those PWH who are currently cared for in
other models. It was acknowledged that integrated
care may not be acceptable to some groups (e.g.
health care practitioners who care for PWH outside of
an integrated care model).
Resource use in different models of care was chal-
lenging to assess. Clotting factor concentrates account
for 92% of total direct medical costs in PWH treated
at HTCs [24]. The panel felt that, if the cost of clot-
ting factor concentrates were assumed to be equal in
all models of care, the additional costs that support
the integrated care model (approximately, 8% of total
direct medical costs in PWH treated at HTCs) would
be worth the benefits seen.
A number of subgroups were considered by the
panel. Disease severity was felt to be an important
consideration. Individuals with mild and moderate
haemophilia were thought to benefit from an initial
visit to an integrated care centre for education,
workup and counselling. However, the frequency of
further follow-up may then be lower than other sub-
groups. Special expertise is required to care for
patients with mild haemophilia. For example, individ-
uals with mild haemophilia and certain mutations are
more likely to develop inhibitors in later life; inhibitor
prevention in these individuals can lead to potential
cost avoidance and better health outcomes [25,26].
The panel also underscored that not all PWH are
male; female carriers can often fall into the category
of ‘mild haemophilia,’ and their unique needs (e.g.
obstetric/gynaecologic care, maternal care) may not
fall within the capacity of all HTCs. Integrated care
models should accommodate the needs of both male
and female PWH.
Individuals with severe haemophilia represent the
other side of the spectrum. Just as clinical conse-
quences and burden of disease appear to be corre-
lated with severity in haemophilia, the balance of
benefits may also be correlated with severity. The
panel felt that their recommendation for integrated
care over other models of care is particularly appli-
cable to individuals with higher burden of disease,
and those with higher resource requirements (e.g.
comorbidities, paediatric or older populations), but
still important for patients with mild and moderate
haemophilia.
Inhibitor status was also considered. The panel
strongly recommended integrated care for inhibitor
patients and those at higher risk for inhibitor develop-
ment (e.g. genotype, family history, invasive proce-
dures), as the overall balance of benefits and harms is
more pronounced. Though relative benefits of the inte-
grated care model are likely the same as the general
haemophilia population, we would expect larger abso-
lute benefits for individuals with inhibitors, as they
are at highest risk of harms (and thus have the most
potential for benefit).
Age was considered by the panel as well. There is
a key opportunity for therapeutic intervention in the
paediatric years (<18 years old) for PWH: prevention
of inhibitor formation; disease-focused education and
counselling; teaching around self-infusion; and laying
the groundwork for future care. Paediatric PWH may
thus benefit from more frequent visits to an inte-
grated care centre. As the haemophilia population
ages, and normal life expectancy becomes a realistic
goal, models of care must also adapt to the older
population. The panel felt that haemophilia care pro-
viders must determine whether they will provide
holistic care for their older patients or develop rela-
tionships with other specialists and primary care pro-
viders outside of the integrated care centre who can
manage comorbidities that may not be directly
related to haemophilia.
Infectious comorbidities were the final subgroup
characteristic considered. HIV and hepatitis inform
burden of disease, and thus may be correlated with
the balance of benefits. The recommendation for inte-
grated care over other models of care is particularly
applicable to these individuals, whose disease is more
complicated to treat and often have higher resource
requirement.
Recommendation: For persons with haemophil-
ia, the Guideline Panel suggests that the inte-
grated care model be used over non-integrated
care models (conditional recommendation, mod-
erate certainty in the evidence).
Recommendation: For persons with haemophilia
with inhibitors, and those at high risk for inhibi-
tor development, the Guideline Panel recom-
mends that the integrated care model be used
over non-integrated care models (strong recom-
mendation, moderate certainty in the evidence).
Question 2: For individuals with haemophilia,
should a haematologist, a specialized haemophilia
nurse, a physical therapist, a social worker or
round-the-clock access to a specialized coagulation
laboratory be part of the integrated care team, vs.
an integrated care team with a lesser complement?
There were no randomized controlled trials or non-
randomized studies comparing the impact of the pres-
ence or absence of different health care professionals
as part of the integrated care team for people with
haemophilia or any of the other chronic diseases.
Therefore, a formal EP was not produced, and avail-
able evidence was presented in the EtD. (See
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Appendix S4: Evidence to Decision Framework for
Question 2.) In brief, two database originated by sur-
vey studies provided data on access to health care pro-
fessionals within an HTC:
1. The Haemophilia Experiences, Results and Oppor-
tunities (HERO) study surveyed 189 PWH and
190 parents of children with haemophilia in the
US [27]. It reported that 84% of PWH see a
haematologist/haemophilia physician for manage-
ment of haemophilia; 75% see a haemophilia
nurse; 40% a physical therapist; 20% a general
practitioner; and 43% see a social worker. US
data from the HERO study also demonstrated that
physical therapist involvement was more common
in people with better quality of life scores (EQ-
5D) and less pain. Social worker and nurse
involvement were more common in people with
increasing pain and disability [28].
2. International data from the HERO study
reported information from 453 parents of chil-
dren with haemophilia receiving care in HTCs
globally. The nurse was involved in the care of
~70% of respondents, and a social worker was
involved in care of ~30% of respondents. Social
worker involvement was more common in par-
ents reporting negative experiences with work,
and with telling friends about their child’s hae-
mophilia [27].
There is also indirect evidence from two systematic
reviews in people with haemophilia:
1. Study of effects of exercise interventions [29]
included two randomized studies of 56 PWH. Dif-
ferences in pain, range of motion and strength
favoured exercise over no exercise.
2. Study of effects of haemophilia on psychosocial
factors reported that quality of life was reduced in
people with haemophilia; education was not
affected but employment may be affected in men
with severe haemophilia [30]. Life satisfaction,
social support, self-esteem, anxiety, social desir-
ability and depression may also be impacted.
Finally, structured experiential data were systemati-
cally gathered from individuals on the Panel and were
incorporated in the EtD: a summary of the elicited
evidence is presented in Box 1.
The overall certainty of the evidence was very low,
as there were no available studies (randomized or
non-randomized) comparing the impact of the pres-
ence or absence of different health care professionals
as part of the integrated health team.
The marked paucity of data was noted by the panel.
Although there was no evidence to support specific
roles, the panel acknowledged that the integrated
model as commonly implemented (physician, nurse,
physical therapist, social worker, round the clock lab-
oratory) produces a benefit and there is a clear
balance in favour of the full complement of listed
components as part of the integrated care team based
on benefits and harms.
Equity, feasibility and acceptability were all felt to
be enhanced by the full complement of listed compo-
nents as part of the integrated care team. In particular,
this option was judged to be acceptable to key stake-
holders, and highly implementable based on the cur-
rent existence of fully staffed HTCs in the US. In
other words, the uncertainty about feasibility and
acceptability of the intervention was greatly reduced
by the widespread diffusion of the model across US
and beyond.
Box 1 Summary of results from the system-
atic observations completed by the panel
members
1. Haematologist: most indicated moderate to
large benefit of this individual for all outcomes
2. Specialized haemophilia nurse: most indicated
moderate to large benefit of this individual for
all outcomes
3. Physical therapist: most indicated small benefit
of this individual for most outcomes, but large
to moderate benefit for joint damage/disease,
and small to no effect for mortality or costs
4. Social worker: most indicated small benefit to
no effect of this individual for most outcomes,
but large to moderate benefit for quality of life
5. Specialized coagulation laboratory: most indi-
cated that there was no effect of this component
for most outcomes, but a large benefit for cost
6. One panel member reported that before the
Universal Data Collection (UDC) project began,
complete joint range of motion data for all 10
joints on about 1600 haemophilia patients
receiving care from HTCs in six participating
states could be found in the medical records of
less than 1% (Personal communication, J. M.
Soucie) Furthermore, data on joint range of
motion were completely missing for 60% of
patients in these HTCs. However, during the
13 years of UDC data collection which
increased HTC access to trained physical thera-
pists, range of motion data were available on
all 10 joints on an average of 5000–6000 hae-
mophilia patients receiving care in HTCs in
nearly 90% of cases, whereas these data were
completely missing for less than 5% of the
patients. The Panel Member noted that most
HTCs had to hire physical therapists to perform
these measurements.
© 2016 John Wiley & Sons Ltd Haemophilia (2016), 22 (Suppl. 3), 6--16
CARE MODELS FOR HAEMOPHILIA 11
There were no available data to assist the panel in
estimating the resources required for the full comple-
ment of listed components as part of the integrated
care team, nor was there certainty about whether the
incremental costs were small relative to the net
benefits.
For Recommendation 2, the panel had less confi-
dence in the recommendation, as there was very low
certainty in the evidence and the panel was unable to
determine the relative impact of each component of
the integrated care team. The haematologist, nurse,
physical therapist, social worker and specialized coag-
ulation laboratory were identified as components of
interest by the panel, as they make up the current
standard ‘core team’ for US HTCs. The final recom-
mendation for question 2 focused on the synergistic
effect of these core components, and supported the
idea that changing or removing any one component
may potentially impact the entire team.
Lack of data limited the panel’s ability to make
statements about specific subgroups. However, just as
the clinical consequences/burden of disease with hae-
mophilia appear to be correlated with certain factors
(severity, inhibitors, age, infectious comorbidities), the
balance of benefits may also be correlated with these
factors. Thus, the recommendation for the full com-
plement of integrated care components may be partic-
ularly applicable to individuals with a higher burden
of disease and those with higher resource require-
ments. The panel noted that the paediatric age group
presents a key opportunity for therapeutic interven-
tion, so a range of expert health care providers is
likely necessary to provide these interventions. Simi-
larly, as PWH age and develop additional comorbidi-
ties unrelated to their bleeding disorder, they may
require access to different health care providers than
those usually present in an integrated care centre (e.g.
older population, cardiology). Integrated care centres
must consider how to ensure that older PWH have
access to this care.
Recommendation: For individuals with haemophil-
ia, the Panel suggests that a hematologist, a spe-
cialized haemophilia nurse, a physical therapist,
a social worker, and round-the-clock access to a
specialized coagulation laboratory be part of the
integrated care team, over an integrated care
team that does not include all of these compo-
nents (conditional recommendation, very low
certainty in the evidence).
Implementation considerations and monitoring
Question 1: Should integrated care vs. non-
integrated care be used for people with
haemophilia?
Patient access is vital to the success of the integrated
care model. Access challenges could be addressed by
telehealth, outreach clinics or hub and spoke strategies;
these features (which were beyond the scope of the cur-
rent guideline) could make the integrated care model
more feasible. They merit further study. The panel
notes that access to care varies based on geographic
location, race/ethnicity and insurance status. As part
of the panel’s recommendation for integrated care, it
encourages individual integrated care centres and the
US HTC network to be mindful of access issues, and
take steps to rigorously evaluate and address them.
Integrated care centres must also optimize their capac-
ity to care for PWH. The panel cited that stable fund-
ing for integrated care centres might improve capacity,
overall implementability and outcomes.
The panel acknowledges that PWH may also
access care differently based on their unique charac-
teristics. For example, the frequency of visits may
depend on the severity of disease, and PWH may
need different components of the integrated care at
different times. Age may also affect the frequency of
visits in an inverse fashion (e.g. with paediatric
patients seen more frequently). Integrated care must
reflect this diversity of patient needs. Further, cir-
cumstances may dictate that PWH seek care from
different integrated care centres, or different settings,
as not all integrated care centres are equivalent. For
example, female carriers, who often exhibit a mild
bleeding phenotype, may prefer HTCs that offer spe-
cialized obstetric/gynaecologic care. It is of primary
importance that the care of patients with haemophi-
lia must be guided by individuals with sufficient
clinical expertise.
Finally, the panel highlights the importance of uni-
fied data systems in US HTCs, to facilitate dynamic
ongoing monitoring of models of care and their
impact on patient-important outcomes.
Question 2: For individuals with haemophilia,
should a haematologist, a specialized haemophilia
nurse, a physical therapist, a social worker or
round-the-clock access to a specialized coagulation
laboratory be part of the integrated care team, vs.
an integrated care team with a lesser complement?
Standardization is needed to define the components of
the integrated care model, and lay out performance
metrics (that take into consideration the impact of
care on patient outcomes). These are currently lack-
ing. The panel advocates that integrated care models
aim to standardize their different components of care
to minimize practice variations. The standardization
of these components, and their impact on patient-
important outcomes, should be evaluated.
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The panel has made a recommendation on the mini-
mum team cohort for integrated care centres – a
physician, a nurse, a physical therapist, a social
worker and a specialized coagulation laboratory.
However, as noted above, PWH have unique
needs and characteristics, so there may be situations
where there is a need for additional health care provi-
ders or components of care. Demographic studies have
confirmed that the natural history of haemophilia is
changing [31–33]. Moreover, the US health care
system is also changing. Thus, it is important that inte-
grated care centres respond to the needs of their
patient population in a dynamic way, to ensure the
long-term sustainability of these centres.
The panel’s recommendations around components
of care refer to the current state of haemophilia care
in the US; they acknowledge that the landscape of
health care systems and insurance is changing
rapidly. Integrated care centres and the larger
haemophilia community must optimize their ability
to train, recruit and retain specialized health
care team members to meet the needs of PWH.
This would ensure that all integrated care centres
have a standardized team of expert health care
providers.
Research priorities
Question 1: Should integrated care vs. non-
integrated care be used for persons with
haemophilia?
The panel noted gaps in data when it considered the
population, the intervention, the outcomes and the
certainty of the evidence. They indicated the need for
research to address these gaps:
1. Populations that should be studied: older popula-
tions (≥65 years old), populations with poor access
to care (in order to identify barriers to care and
better integrate them into current models of care),
PWH who access care outside of HTCs or inte-
grated care models.
2. Interventions that should be studied: The impact
of telemedicine, outreach clinics and other remote
care delivery systems as an alternative/add-on to
integrated care would be useful, and the panel
noted that there is ongoing research taking place
in these areas. Randomized trials may be possible
to answer these questions.
3. Outcomes that should be studied: the cost and
effectiveness of care outside of HTCs is not
known. Further, data on factor utilization within
and outside of HTCs is not available, and there
are limited data on lost days of school/work,
educational attainment or employment attain-
ment within and outside HTCs. There is a
potential for well-designed retrospective matched
cohort studies or prospective data collection to
address this gap.
4. Qualitative data may address barriers to care, par-
ticularly in non-HTC patients.
5. Studies identifying predictive factors for poor out-
comes in different models of care would be valu-
able.
6. European guidelines have recommended that
HTCs be active in data collection [34]. US HTCs
must build further capacity to collect and analyze
data, in order to power higher quality, comprehen-
sive studies. There must also be continued efforts
to address the dearth of data in the non-HTC pop-
ulation.
Question 2: For individuals with haemophilia,
should a haematologist, a specialized haemophilia
nurse, a physical therapist, a social worker or
round-the-clock access to a specialized coagulation
laboratory be part of the integrated care team, vs.
an integrated care team with a lesser
complement?
The panel noted significant gaps in data when it con-
sidered the population, the intervention, the outcomes
and the quality of the evidence. They cited the need
for research to address these gaps, and define the truly
necessary and essential components of the integrated
care team:
1. Populations that should be studied: older popula-
tions, populations with poor access to care (in
order to identify barriers to care and better inte-
grate them into current models of care).
2. Interventions that should be studied: it is unclear
which aspects of the integrated care model add
value, as current data reflect a very heterogeneous
group of models. The haemophilia community
must consider if randomized trials are possible to
answer these questions or if research could be con-
ducted in other (non-US) settings. The latter may
offer opportunities to study teams with a smaller
complement of health care providers. If financial
resources limit the ability of US HTCs to offer the
full complement of health care providers in all
HTCs simultaneously, a staggered cluster random-
ized trial (with HTCs as the unit of randomiza-
tion) to look at patient-important outcomes may
be feasible.
3. Outcomes that should be studied: though there
are published data that look at the impact of
integrated care on patient-important outcomes,
they are scarce. Further, there are limited data
that look at the impact of individual components
of the integrated care team, or that consider
the impact of the individual who delivers it
(e.g. physical therapist), not of the intervention
© 2016 John Wiley & Sons Ltd Haemophilia (2016), 22 (Suppl. 3), 6--16
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(e.g. exercise). This focused research would be
useful.
4. Qualitative data may prove valuable in addressing
equity, feasibility and acceptability issues.
5. As per this Guideline’s first recommendation,
the panel again recommends that US HTCs build fur-
ther capacity for data collection and analysis.
Conclusion
Using an evidence-based methodology, the NHF-
McMaster Guideline on Care Models for Haemophilia
Management suggests an integrated care model for
people with haemophilia. Major strengths of this
guideline are its development by a panel of relevant
stakeholders, the rigorous process to minimize conflict
of interest, the use of innovative evidence gathering
strategies (i.e. formal assessment of indirectness, use
of systematic observations) and its transparent, evi-
dence-based development approach. Although there
was a limited amount of direct, high-quality evidence
pertaining to models of care delivery in haemophilia,
and a paucity of data addressing some patient-impor-
tant outcomes, resource use, and impact on equity,
feasibility and acceptability, the panel considered all
of these factors to make recommendations based on
the best available evidence to date. For this reason,
the panel has supplemented its recommendations with
clear suggestions to guide NHF and the broader hae-
mophilia community in setting research priorities to
consolidate and expand the evidence base of these rec-
ommendations.
In conclusion, a qualified panel of non-conflicted,
relevant stakeholders has issued, using a transparent
and rigorous methodology, unanimous support of the
provision of integrated care for people with
haemophilia.
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